GENE ONLINE|News &
Opinion
Blog

2022-05-20| COVID-19R&D

Genetics May Be a Factor in Varying COVID-19 Severity

by Fujie Tham
Share To

Someone may have been exposed but seems COVID-proof, or some were infected with barely noticeable symptoms, while some got really sick. Questions on why the virus acts so unpredictably are piling up as multivariant vaccine development remains slow, all while Omicron variant’s driving reinfections globally. Immunologists, microbiologists are now turning to human genetics for answers.

 

Human’s Built-In Resistance

 

Our evolution has been driven by sufficiently pathogenic microbes that apply selective pressure on genes crucial for defenses. In an international study published on Nature, researchers are screening and studying the genetics of individuals believed to be resistant to SARS-CoV-2 infection, trying to understand what might make a person extra vulnerable, or protected from COVID-19. 

At the pandemic’s beginning, studies identified that SARS-CoV-2 relies on ACE2 (angiotensin converting enzyme 2) receptors for cell entry, and protease TMPRSS2 for spike protein priming. The study suggested that rare genetic variants, such as ACE2 variant rs190509934 located close to the ACE2 sequence could contribute to decreased ACE2 expression, thereby protecting against COVID-19 infection. The team has already recruited over 400 individuals in their next dedicated resistance study cohort. 

Related article: Pfizer to Address COVID-19 Reinfection After Treated by Paxlovid 

 

Mild or Severe COVID-19?

 

Investigation of genetic diversity and detection of natural selection signatures in human genes related to COVID-19 infection will help identify functionally significant variations. According to University of Pennsylvania’s scientists, variants of four SARS-CoV-2 infection-related genes were targets of natural selection and linked to health conditions observed in patients. The genes are angiotensin converting enzyme 2 (ACE2), transmembrane protease serine 2 (TMPRSS2), dipeptidyl peptidase 4 (DPP4), and lymphocyte antigen 6 complex locus E (LY6E).

Being the first study to look at ethnically diverse Africans and a highly diverse dataset from the Penn Medicine BioBank, the team discovered 41 global rare variants of the ACE2 gene that affected the amino acid sequence of the protein, as well as 48 variants of TMPRSS2, some are also found with unique characteristics that may be the answer to contrasting COVID-19 susceptibility. 

While above research shined a light on new understanding of SARS-CoV-2 and could be developed into treatments, more work is still required to investigate the impact of genetic variation on population’s response to COVID-19 infection.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top